New pharmacological approaches for the treatment of alcoholism

@article{Soyka2006NewPA,
  title={New pharmacological approaches for the treatment of alcoholism},
  author={M. Soyka and S. Roesner},
  journal={Expert Opinion on Pharmacotherapy},
  year={2006},
  volume={7},
  pages={2341 - 2353}
}
Pharmacological relapse prevention in alcoholism is a rather new clinical field with few drugs being available. Acamprosate, acting predominantly via glutamatergic pathways, and the opioid receptor antagonist naltrexone, were both shown to be efficient in improving rates for continuous abstinence, and not relapsing to heavy drinking in a number of clinical trials and meta-analyses. There are conflicting data on both drugs, especially for acamprosate, according to some recent US studies. However… Expand
Glutamatergic substrates of drug addiction and alcoholism.
The past two decades have witnessed a dramatic accumulation of evidence indicating that the excitatory amino acid glutamate plays an important role in drug addiction and alcoholism. The purpose ofExpand
Treatment of alcohol dependence in patients with co-morbid major depressive disorder – predictors for the outcomes with memantine and escitalopram medication
BackgroundAlcohol dependence comorbid with major depressive disorder poses a major challenge in the clinical setting. The results in the treatment with selective serotonin re-uptake inhibitors haveExpand
The effects of alcohol on neurotransmitters appear to mediate the risk for alcohol use disorder : a brief update
These practice guidelines for the biological treatment of alcohol use disorders are an update of the first edition, published in 2008, which was developed by an international Task Force of the WorldExpand
Guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism, first revision
TLDR
These practice guidelines for the biological treatment of alcohol use disorders are an update of the first edition published in 2008 and provide a clinically and scientifically relevant, evidence-based update of earlier recommendations. Expand
Baclofen improves abstinence in alcoholic cirrhosis: Still better to come?
TLDR
Baclofen is effective at promoting alcohol abstinence in alcohol-dependent patients with liver cirrhosis, the drug is well tolerated and could have an important role in treatment of these individuals. Expand
Neurobiology, Genetics and Treatment of Alcohol Craving
Alcohol craving has increasingly been considered an important issue in alcohol use disorders in the last decade. Biologic studies on alcohol craving were mainly focused on neurobiology, genetics andExpand
Pharmaco-EEG-based assessment of interaction between ethanol and levetiracetam.
TLDR
Combined administration of ethanol and levetiracetam resulted in a markedly synergistic effect in the frontal cortex and the midbrain reticular formation and decreases the sensitivity of the hippocampus to ethanol, an observation that may be important in the treatment of alcohol addiction. Expand
Pharmaco-EEG-based assessment of the interaction between ethanol and oxcarbazepine.
TLDR
Oxcarbazepine altered the EEG pattern in rabbits and decreased the sensitivity of the hippocampus to ethanol, an observation that may be important for the treatment of alcohol addiction. Expand
Pharmaco-EEG-based assessment of interaction between ethanol and topiramate Bogus 3
Topiramate, an anticonvulsant, has been reported to increase the number of abstinent days and decrease craving in alcohol-dependent individuals. However, maintaining abstinence during the therapy ofExpand
Impulse Control Disorders and Pathological Gambling in Patients With Parkinson Disease
TLDR
Patients most commonly affected by ICD, such as pathologic gambling and hypersexuality, are males who develop PD at a younger age, and those with a previous history of mood disorder, alcohol abuse, or obsessive-compulsive disorder. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 144 REFERENCES
Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis.
TLDR
Both naltrexone and acamprosate are efficacious in reducing alcohol consumption in alcoholics, however, their specific role in alcoholism treatment remains to be more clearly defined. Expand
Neuropharmacological treatments for alcoholism: scientific basis and clinical findings
TLDR
Of the medications reviewed, acamprosate’s potential appears to be the most widely established and ondansetron, a serotonin3 antagonist, offers new hope for the treatment of early onset alcoholics; a type of alcoholism most difficult to manage with psychosocial measures alone. Expand
Update on anticonvulsants for the treatment of alcohol withdrawal.
TLDR
Controlled trials are underway exploring the efficacy and safety of newer anticonvulsants for the treatment of alcohol withdrawal, including gabapentin and vigabatrin, which appear to reduce alcohol withdrawal symptoms in preclinical and open-label clinical trials while lacking the toxicities of carbamazepine and divalproex. Expand
Pharmacological treatment of alcohol dependence: a review of the evidence.
TLDR
Evaluating the efficacy of 5 categories of drugs used to treat alcohol dependence found some evidence that drinking frequency is reduced but minimal evidence to support improved continuous abstinence rates, and recent reports documenting that naltrexone and acamprosate are more effective than placebo justify clinical interest in use of these medications for alcohol-dependent patients. Expand
Double-Blind Clinical Trial of Sertraline Treatment for Alcohol Dependence
TLDR
Sertraline treatment seemed to provide an advantage in reducing drinking in alcohol-dependent patients without lifetime depression, illustrated best with a measure of drinking frequency during treatment, however, sERTraline was no better than placebo in patients with a diagnosis of lifetime comorbid depression, and current depression did not change the results. Expand
The use of divalproex in alcohol relapse prevention: a pilot study.
TLDR
While DVPX did not have a robust effect on alcohol-related outcomes, it did have modest impact on a measure of irritability, consistent with the findings of other investigators exploring the use of DVPx in schizophrenia, personality disorder and a number of other psychiatric disorders. Expand
Naltrexone in the treatment of alcoholism.
TLDR
A safe and well-tolerated opiate antagonist, naltrexone, was approved by the Food and Drug Administration for the adjunctive treatment of alcoholism and the pertinent preclinical and clinical research that led to the FDA's approval is described. Expand
Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial.
TLDR
Motivated individuals with moderate alcohol dependence can be treated with greater effectiveness when naltrexone is used in conjunction with weekly outpatient cognitive behavioral therapy. Expand
A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence.
TLDR
Despite the small sample size, compliance difficulties after 4 months and a sizable drop-out rate, there were treatment effects favoring carbamazepine, and these pilot results are encouraging and support carbazepine as a possible pharmacologic tool in the treatment of alcohol dependence. Expand
Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, Part 2.
  • G. A. Kenna, J. McGeary, R. Swift
  • Medicine
  • American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
  • 2004
TLDR
In addition to existing drug treatments for alcohol dependence, many other medications are under investigation, particularly for specific types of alcoholism, and Pharmacogenomics is expected to play an important role in this research effort. Expand
...
1
2
3
4
5
...